Pharmaceuticals

Global Next Generation Complement Therapeutics Market Set To Expand To $1.36 Billion By 2030 At 10.4% CAGR

May 1, 2026May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Next Generation Complement Therapeutics Market Grow Between 2026 And 2030?

The next generation complement therapeutics market size has seen rapid expansion in recent years. It is forecast to grow from $7.38 billion in 2025 to $8.56 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 16.0%. The increase observed in the past can be attributed to the limited availability of complement-targeting therapeutics, a reliance on conventional immunosuppressive therapies, the growing prevalence of rare hematologic and autoimmune disorders, regulatory approvals granted for first-generation complement inhibitors, and an increase in clinical trials in hematology and ophthalmology.

The next generation complement therapeutics market size is anticipated to undergo significant expansion in the coming years. It is forecast to achieve a valuation of $15.29 billion in 2030, growing at a compound annual growth rate (CAGR) of 15.6%. The expansion during this forecast period can be attributed to several factors, including the development of novel c3, c5, factor b, and factor d inhibitors, the widening application of combination therapy methods, the increasing embrace of gene and rna-based medicines, greater investment in rare disease research, and rising healthcare spending on advanced immune therapies. Prominent trends for the forecast duration include a greater acceptance of targeted complement therapies for rare diseases, an increase in both monotherapy and adjunctive therapy approaches, the growing utilization of biologics and small molecule complement inhibitors, the broadening of applications within ophthalmology, hematology, and immunology, and the integration of personalized medicine with gene-based therapeutics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27360&type=smp

Which Important Drivers Are Guiding The Next Generation Complement Therapeutics Market Growth?

The increasing incidence of chronic diseases is projected to propel the expansion of the next-generation complement therapeutics market. Chronic ailments are persistent health conditions necessitating continuous care to manage symptoms and enhance quality of life. The surge in these conditions primarily stems from inactive lifestyles, which restrict physical activity, disrupt metabolic processes, and heighten long-term health concerns. Next-generation complement therapeutics address chronic diseases by accurately targeting and regulating the hyperactive complement system, thereby mitigating inflammation and averting tissue damage. For example, in June 2024, data from the National Health Service, a UK-based government department, revealed that 3,615,330 individuals registered with a general practitioner (GP) had been diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023. This represented an 18% rise from 3,065,825 cases recorded in 2022. Consequently, the growing prevalence of chronic diseases is stimulating the growth of the next-generation complement therapeutics market.

How Is Segmentation Applied In The Next Generation Complement Therapeutics Market Segment Analysis?

The next generation complement therapeutics market covered in this report is segmented –

1) By Type Of Therapy: Monotherapy, Adjunctive Therapy

2) By Molecule Type: Biologic, Small Molecule

3) By Route Of Administration: Intravenous, Oral, Intravitreal, Subcutaneous

4) By Indication: Paroxysmal Nocturnal Hemoglobinuria, Geographic Atrophy (GA) Secondary To Age-Related Macular Degeneration, Generalized Myasthenia Gravis, Atypical Hemolytic Uremic Syndrome, Other Indications

5) By Therapeutic Area: Hematology, Ophthalmology, Neurology, Immunology Or Rheumatology, Other Therapeutic Areas

Subsegments:

1) By Monotherapy: C3 Inhibitors, C5 Inhibitors, Factor D Inhibitors, Factor B Inhibitors, C1 Inhibitors, MASP-2 Inhibitors

2) By Adjunctive Therapy: Combination With Immunosuppressants, Combination With Steroids, Combination With Plasma Exchange, Combination With Biologics, Combination With Chemotherapeutics, Combination With Anticoagulants

What Trends Are Transforming The Next Generation Complement Therapeutics Market?

Leading companies operating in the Next Generation Complement Therapeutics market are dedicating efforts to developing inventive solutions, such as targeted C5 complement inhibitors, to address the increasing need for effective treatments for rare and severe complement-mediated diseases. These targeted C5 complement inhibitors are designed to selectively obstruct the C5 protein within the complement cascade, thereby preventing the formation of the membrane attack complex, a critical step in immune-mediated tissue damage. For example, in February 2024, Chugai Pharmaceutical Co., Ltd., a Japan-based biopharmaceutical company, introduced PEGPH20 (Pegcetacoplan), an innovative C5-targeted complement inhibitor. PEGPH20, a synthetic peptide conjugate, is specifically engineered to selectively inhibit complement C5 activation, thus preventing hemolysis and inflammation associated with conditions like paroxysmal nocturnal hemoglobinuria (PNH) and other complement-driven disorders. This therapy offers benefits such as subcutaneous administration, improved patient compliance, and a favorable safety profile when compared to traditional systemic complement inhibitors.

Who Are The Companies Participating In The Next Generation Complement Therapeutics Market Environment?

Major companies operating in the next generation complement therapeutics market are AstraZeneca PLC, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Genmab A/S, Mallinckrodt Pharmaceuticals Ltd., Alnylam Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Omeros Corporation, CANbridge Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Molecular Partners AG, NovelMed Therapeutics Inc., InflaRx GmbH, Amyndas Pharmaceuticals S.A., Kira Pharmaceuticals Inc., ReAlta Life Sciences Inc.

Get The Full Next Generation Complement Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/next-generation-complement-therapeutics-global-market-report

Which Region Leads The Next Generation Complement Therapeutics Market In Overall Market Size?

North America was the largest region in the next generation complement therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation complement therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Next Generation Complement Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/next-generation-complement-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Next Generation Complement Therapeutics Market 2026, By The Business Research Company

Payment Gateway Market Report 2026

https://www.thebusinessresearchcompany.com/report/payment-gateway-global-market-report

Payment Processor Market Report 2026

https://www.thebusinessresearchcompany.com/report/payment-processor-global-market-report

Quantum Technology Market Report 2026

https://www.thebusinessresearchcompany.com/report/quantum-technology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795